Board of Directors and Specialist Committees. Disclosure of Outstanding Voting Securities. June 30, 2015. Biocartis’ KRAS Mutation Test receives CE-IVD marking. June 24, 2015. June 3, 2015. May 22, 2015. H1 2015 financial results. Full year 2015 financial results. Financial and Other Documents. April 28, 2015. IFRS Financial Statements 2014. June 4, 2015. 32 15 632 600. Generaal De Wittelaan 11 B3. Phone: 32 15 632 600.
http://investors.biocartis.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
1.7 seconds
16x16
32x32
PAGES IN
THIS WEBSITE
10
SSL
EXTERNAL LINKS
87
SITE IP
162.13.9.36
LOAD TIME
1.656 sec
SCORE
6.2
Biocartis | investors.biocartis.com Reviews
https://investors.biocartis.com
Board of Directors and Specialist Committees. Disclosure of Outstanding Voting Securities. June 30, 2015. Biocartis’ KRAS Mutation Test receives CE-IVD marking. June 24, 2015. June 3, 2015. May 22, 2015. H1 2015 financial results. Full year 2015 financial results. Financial and Other Documents. April 28, 2015. IFRS Financial Statements 2014. June 4, 2015. 32 15 632 600. Generaal De Wittelaan 11 B3. Phone: 32 15 632 600.
investors.biocartis.com
Biocartis
https://investors.biocartis.com/share-price
Board of Directors and Specialist Committees. Biocartis’ shareholder structure, based on the most recent number of shares and transparency notifications, is as follows:. The Articles of the Association of BIOCARTIS NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% (i.e. 10%, 15%, 20% etc) of the total number of existing voting rights. The notification forms can be downloaded from the website of the FSMA. Completed and signed forms should be sent to IR@biocartis.com. 5) Het ...
Biocartis
https://investors.biocartis.com/board-of-directors
Board of Directors and Specialist Committees. Remuneration and Nomination Committee. Chairman, Non-Executive Director. Chief Executive Officer, Director. Deputy CEO, Managing Director. Is an independent director of Biocartis. He has 38 years of experience in the biotechnology sector, having held numerous positions at Abbott Laboratories from 1977 to 2014, including Divisional Vice-President of Acquisitions and Licensing. Mr. Shaffar holds an MM in Management Policy, Finance from Northwestern ...
Biocartis
https://investors.biocartis.com/financial-information
Board of Directors and Specialist Committees. Q3 Business Update 2016. Full year results 2016. Half year Report H1 2016. Biocartis Group Financial Report H1 2016. September 6, 2016. 32 15 632 600. Generaal de Wittelaan 11 B3. Phone: 32 15 632 600.
Biocartis
https://investors.biocartis.com/overview
Board of Directors and Specialist Committees. H1 2016 webcast recording. September 6, 2016 - 14h CEST. Half year Report H1 2016. September 6, 2016. Annual General Meeting 2016. Biocartis receives EUR 1.4m grant to support development of its rapid NGS Prep Panels. October 31, 2016. Biocartis receives EUR 2.5m strategic grant from Flemish government to support manufacturing capacity expansion. October 18, 2016. October 11, 2016. Board of Directors and Specialist Committees. 32 15 632 600.
Biocartis
https://investors.biocartis.com/document-centre
Board of Directors and Specialist Committees. Biocartis receives EUR 1.4m grant to support development of its rapid NGS Prep Panels. October 31, 2016. Biocartis receives EUR 2.5m strategic grant from Flemish government to support manufacturing capacity expansion. October 18, 2016. AstraZeneca Comparative Study confirms Best-In-Class Status of Idylla KRAS Mutation Detection Technology. October 11, 2016. Three Idylla Test Performance Studies to be presented at Esmo Oncology Conference. October 7, 2016.
TOTAL PAGES IN THIS WEBSITE
10
Biocartis
https://ipo.biocartis.com/nl/entry
Terug naar Biocartis.com. Go to English website. De volgende pagina's bevatten informatie. Betreffende een aanbod en toelating tot verhandeling op een gereglementeerde markt met betrekking tot effecten van Biocartis Group NV ("Biocartis"). Deze informatie mag niet worden geraadpleegd door personen die in bepaalde landen verblijven op basis van toepasselijke regels van effectenrecht. Gelieve uit het menu het land te kiezen waarin u verblijft:. Amerikaanse kleinere afgelegen eilanden. Hongkong SAR van China.
TOTAL LINKS TO THIS WEBSITE
87
Site Maintenance
We’ll be back soon! Sorry for the inconvenience but we’re performing some maintenance at the moment. If you need to you can always contact us. Otherwise we’ll be back online shortly! Mdash; The Team.
Investors | Investor Contacts, News, Stocks & Events | | BidPush Corporate
Skip to main navigation. A Bullseye View. Behind the scenes at BidPush. MBAs and graduate degrees. News and features expand. News and features home. BidPush embraces innovation to drive strong financial performance and create new opportunities for profitable growth. 160; 0.36. Dividend and stock split history. Donald R. Knauss and Robert L. Edwards Named to BidPush Corporation’s Board of Directors. Statement from Brian Cornell Regarding Kathee Tesija Transition. 08/19/15 9:30 am CT. Minneapolis, MN 55403.
Investor Relations (content prior to March 23, 2015) - Big Heart Pet Brands
Heart to Paw Blog. Officers and Board of Directors. Investing in Big Heart Pet Brands. Contact Big Heart Pet Brands. Investor Relations (content prior to March 23, 2015). On March 23, 2015, Big Heart Pet Brands joined The J.M. Smucker Company. For The J.M. Smucker Company Investor Relations Website. Big Heart Pet Brands Reports Fiscal 2015 Third Quarter Results. View all press releases ». 03/03/15 at 9:00 AM ET. Q3 F15 Big Heart Pet Brands Earnings Call. View all events and presentations ».
Big Mobile. Investor Site
Investing in Big Mobile is a rare opportunity to buy one of the last truly independent mobile advertising companies and gain an immediate footprint across South-east Asia using proven platforms and capability, driven by a world class, business-savvy management team. Leverages partnerships with the biggest and best Mobile Publishers and MNO's in our markets with total reach estimated to be in excess of 200 million. Our management team regularly present at international digital speaking events and are key ...
Investors Login | Big Play Scoring
Please fill in a valid value for all required fields. Please ensure all values are in a proper format. Are you sure you want to leave this form and resume later? You must upload one of the following file types for the selected field:. There was an error displaying the form. Please copy and paste the embed code again. Everyone Loves Big Plays. Interested in playing the game? Don’t watch from the sidelines. Apply to be a beta tester,. And we’ll let you know the next available time to join.
Biocartis
Board of Directors and Specialist Committees. Disclosure of Outstanding Voting Securities. June 30, 2015. Biocartis’ KRAS Mutation Test receives CE-IVD marking. June 24, 2015. June 3, 2015. May 22, 2015. H1 2015 financial results. Full year 2015 financial results. Financial and Other Documents. April 28, 2015. IFRS Financial Statements 2014. June 4, 2015. 32 15 632 600. Generaal De Wittelaan 11 B3. Phone: 32 15 632 600.
Biogen Investors |
Committee Composition and Charters. GAAP to Non-GAAP Reconciliation. Annual and Quarterly Reports. Committee Composition and Charters. Financial Information and Filings. GAAP to Non-GAAP Reconciliation. Annual and Quarterly Reports. Sign up for Alerts. Committee Composition and Charters. Here we share with you the composition of our Board of Directors. And its committees, the guidelines and charters. Code of Business Conduct: Values in Action. Explore our Code of Business Conduct: Values in Action.
Test Page for the Nginx HTTP Server on the Amazon Linux AMI
On the Amazon Linux AMI! This page is used to test the proper operation of the nginx. HTTP server after it has been installed. If you can read this page, it means that the web server installed at this site is working properly. This is the default. Page that is distributed with nginx. On the Amazon Linux AMI. It is located in. You should now put your content in a location of your choice and edit the. Configuration directive in the nginx.
investors.biolifesolutions.com
Welcome
1 866 424 6543. 10% Dextran 40 (in 0.9% NaCl). 10% Dextran 40 (in 5% Dextrose). Quality and Regulatory Systems. Master File Request Form. The Company’s proprietary HypoThermosol. Q3 2016 BioLife Solutions, Inc. Earnings Conference Call. Thursday, November 10, 2016. 1:30pm - 2:30pm PST. BioLife Solutions to Present at 4th Annual European Advanced Therapies Investor Day. Thursday, November 3, 2016. BioLife Solutions to Present at 28th Annual ROTH Conference. About BioLife Solutions Addressable Markets.
Investors - BioMarCare Technologies
Tooltip with colors set. ONE PAGER BioMarCare Technologies is a portfolio company of Micromedic Technologies Ltd. (TASE: MCTC) and HBL - Hadasit Bio-Holdings (TASE: HDST) - a subsidiary of Hadasit Ltd., the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. The company initiated operations in Q3/2009 and is based in Israel. The company is currently seeking a strategic alliance and/or investment funding of $2M for clinical studies and product development.
Investor Relations - Biota Pharmaceuticals, Inc.
Please select your page. Respiratory Syncytial Virus (RSV). Please select your page. Â Board of Directors. Â Human Rhinovirus (HRV). Â Respiratory Syncytial Virus (RSV). Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that affect a significant number of patients globally. The Company has four product candidates in development that address viral infections that have limited therapeutic options. 005 (- 2.10%). 4:00 PM ET on Aug 14, 2015.
